Ken Takeshita, Daiichi Sankyo global head of R&D

En­her­tu strikes again with a PhI­II suc­cess in an­oth­er breast can­cer pop­u­la­tion

An­oth­er sum­mer day, an­oth­er En­her­tu up­date.

The As­traZeneca-Dai­ichi Sankyo an­ti­body-drug con­ju­gate has passed an­oth­er tri­al, this time a Phase III tri­al test­ing the can­cer drug ver­sus physi­cian’s choice in pa­tients with HER2-pos­i­tive metasta­t­ic breast can­cer.

The DES­TINY-Breast02 study beat out the oth­er treat­ments — trastuzum­ab/capecitabine or la­p­a­tinib/capecitabine — in im­prov­ing pro­gres­sion-free sur­vival and a sec­ondary end­point, over­all sur­vival.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.